A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1-Reference-Cited by-同舟云学术

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Published:2013-10-10 Issue:10 Volume:8 Page:e76280
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yabuki Chiori,Komatsu Hidetoshi,Tsujihata Yoshiyuki,Maeda Risa,Ito Ryo,Matsuda-Nagasumi Kae,Sakuma Kensuke,Miyawaki Kazumasa,Kikuchi Naoya,Takeuchi Koji,Habata Yugo,Mori Masaaki

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40;Y Itoh;Nature,2003

2. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids;CP Briscoe;J Biol Chem,2003

3. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice;K Nagasumi;Diabetes,2009

4. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets;T Alquier;Diabetes,2009

5. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition;K Matsuda-Nagasumi;Diabetes Obes Metab,2013

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes;Biomedicine & Pharmacotherapy;2024-08

2. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-11

3. Exploring structure-based drug discovery of GPCRs beyond the orthosteric binding site;hLife;2024-05

4. GPCRs involved in metabolic diseases: pharmacotherapeutic development updates;Acta Pharmacologica Sinica;2024-02-07

5. Structural basis for the ligand recognition and signaling of free fatty acid receptors;Science Advances;2024-01-12